“Perhaps we could put a list of questions together to send her, that she can pass on to Nader for the CC?”

This is a great idea and something that we as a board have done in the past. The questions during these CCs and web conferences are getting ridiculous. How many times is Rich from Rich’s Investments LLC going to ask through what mechanism does leronlimab fight COVID or how does leronlimab compare to remdesevir?

My one question: Has the second NASH preclinical study been initiated yet? This is the study that Dr. Kelly proposed because the same study got another biotech a large licensing deal.